Cargando…
Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy
The clinical outcomes of cancer nanovaccine have been largely impeded owing to the low antigen-specific T cell response rate and acquired resistance caused by the immunosuppressive tumor microenvironment (TME). Here, we reported a tumor acidity-responsive nanovaccine to remodel the immunosuppressive...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958467/ https://www.ncbi.nlm.nih.gov/pubmed/35386322 http://dx.doi.org/10.1016/j.bioactmat.2022.03.008 |
_version_ | 1784676949416738816 |
---|---|
author | Xie, Xiaoxue Feng, Yi Zhang, Hanxi Su, Qingqing Song, Ting Yang, Geng Li, Ningxi Wei, Xiaodan Li, Tingting Qin, Xiang Li, Shun Wu, Chunhui Zhang, Xiaojuan Wang, Guixue Liu, Yiyao Yang, Hong |
author_facet | Xie, Xiaoxue Feng, Yi Zhang, Hanxi Su, Qingqing Song, Ting Yang, Geng Li, Ningxi Wei, Xiaodan Li, Tingting Qin, Xiang Li, Shun Wu, Chunhui Zhang, Xiaojuan Wang, Guixue Liu, Yiyao Yang, Hong |
author_sort | Xie, Xiaoxue |
collection | PubMed |
description | The clinical outcomes of cancer nanovaccine have been largely impeded owing to the low antigen-specific T cell response rate and acquired resistance caused by the immunosuppressive tumor microenvironment (TME). Here, we reported a tumor acidity-responsive nanovaccine to remodel the immunosuppressive TME and expand the recruitment of tumor infiltrating lymphocytes (TILs) using hybrid micelles (HM), which encapsulated colony stimulating factor 1 receptor (CSF1-R) inhibitor BLZ-945 and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG-919 in its core and displayed a model antigen ovalbumin (OVA) on its surface (denoted as BN@HM-OVA). The bioactive nanovaccine is coated with a polyethylene glycol (PEG) shell for extending nanoparticle circulation. The shell can be shed in response to the weakly acidic tumor microenvironment. The decrease in size and the increase in positive charge may cause the deep tumor penetration of drugs. We demonstrated that the bioactive nanovaccine dramatically enhance antigen presentation by dendritic cells (DCs) and drugs transportation into M1-like tumor-associated macrophages (TAMs) and tumor cells via size reduction and increasing positive charge caused by the weakly acidic TME. Such bioactive nanovaccine could remodel the immunosuppressive TME into an effector T cells favorable environment, leading to tumor growth inhibition in prophylactic and therapeutic E.G7-OVA tumor models. Furthermore, combining the bioactive nanovaccine with simultaneous anti-PD-1 antibody treatment leads to a long-term tumor inhibition, based on the optimal timing and sequence of PD-1 blockade against T cell receptor. This research provides a new strategy for the development of efficient cancer immunotherapy. |
format | Online Article Text |
id | pubmed-8958467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-89584672022-04-05 Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy Xie, Xiaoxue Feng, Yi Zhang, Hanxi Su, Qingqing Song, Ting Yang, Geng Li, Ningxi Wei, Xiaodan Li, Tingting Qin, Xiang Li, Shun Wu, Chunhui Zhang, Xiaojuan Wang, Guixue Liu, Yiyao Yang, Hong Bioact Mater Article The clinical outcomes of cancer nanovaccine have been largely impeded owing to the low antigen-specific T cell response rate and acquired resistance caused by the immunosuppressive tumor microenvironment (TME). Here, we reported a tumor acidity-responsive nanovaccine to remodel the immunosuppressive TME and expand the recruitment of tumor infiltrating lymphocytes (TILs) using hybrid micelles (HM), which encapsulated colony stimulating factor 1 receptor (CSF1-R) inhibitor BLZ-945 and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG-919 in its core and displayed a model antigen ovalbumin (OVA) on its surface (denoted as BN@HM-OVA). The bioactive nanovaccine is coated with a polyethylene glycol (PEG) shell for extending nanoparticle circulation. The shell can be shed in response to the weakly acidic tumor microenvironment. The decrease in size and the increase in positive charge may cause the deep tumor penetration of drugs. We demonstrated that the bioactive nanovaccine dramatically enhance antigen presentation by dendritic cells (DCs) and drugs transportation into M1-like tumor-associated macrophages (TAMs) and tumor cells via size reduction and increasing positive charge caused by the weakly acidic TME. Such bioactive nanovaccine could remodel the immunosuppressive TME into an effector T cells favorable environment, leading to tumor growth inhibition in prophylactic and therapeutic E.G7-OVA tumor models. Furthermore, combining the bioactive nanovaccine with simultaneous anti-PD-1 antibody treatment leads to a long-term tumor inhibition, based on the optimal timing and sequence of PD-1 blockade against T cell receptor. This research provides a new strategy for the development of efficient cancer immunotherapy. KeAi Publishing 2022-03-11 /pmc/articles/PMC8958467/ /pubmed/35386322 http://dx.doi.org/10.1016/j.bioactmat.2022.03.008 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Xie, Xiaoxue Feng, Yi Zhang, Hanxi Su, Qingqing Song, Ting Yang, Geng Li, Ningxi Wei, Xiaodan Li, Tingting Qin, Xiang Li, Shun Wu, Chunhui Zhang, Xiaojuan Wang, Guixue Liu, Yiyao Yang, Hong Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy |
title | Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy |
title_full | Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy |
title_fullStr | Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy |
title_full_unstemmed | Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy |
title_short | Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy |
title_sort | remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958467/ https://www.ncbi.nlm.nih.gov/pubmed/35386322 http://dx.doi.org/10.1016/j.bioactmat.2022.03.008 |
work_keys_str_mv | AT xiexiaoxue remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT fengyi remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT zhanghanxi remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT suqingqing remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT songting remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT yanggeng remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT liningxi remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT weixiaodan remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT litingting remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT qinxiang remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT lishun remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT wuchunhui remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT zhangxiaojuan remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT wangguixue remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT liuyiyao remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy AT yanghong remodelingtumorimmunosuppressivemicroenvironmentviaanovelbioactivenanovaccinespotentiatestheefficacyofcancerimmunotherapy |